Clinical Trials

200 enrolled

Carcinoma, Renal Cell

NCT02243605 2026-03-18

Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma

90 enrolled 15 charts

Sarcoma, Ewing, Osteosarcoma

NCT04071223 2026-03-18

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

134 enrolled

Carcinoma, Renal Cell

NCT04079712 2026-03-18

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

17 enrolled 12 charts

EndocrineNETThoracic

Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT05012371 2026-03-05

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

90 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT04091750 2026-03-03

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

14 enrolled 9 charts

Dermatologic

Melanoma

NCT04963283 2026-02-10

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

48 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03468218 2026-01-23

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

36 enrolled 11 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04413123 2026-01-21

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

60 enrolled

Carcinoma, Renal Cell

NCT04876456 2026-01-15

A Phase II Trial of Cabozantinib With Patients With Refractory GCTs

50 enrolled

Nonseminomatous germ cell tumor, Neoplasms, Germ Cell and Embryonal, Seminoma

NCT03541902 2026-01-09

Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma

32 enrolled

Carcinoma, Renal Cell, Urologic Neoplasms

NCT04820179 2026-01-07

Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer

30 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT04022343 2026-01-05

Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer

22 enrolled 16 charts

Carcinoma, Renal Cell

NCT04200443 2026-01-05

Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma

72 enrolled

Leiomyosarcoma, Sarcoma

NCT04412629 2025-11-24

Cabozantinib in High Grade Neuroendocrine Neoplasms

35 enrolled

Endocrine

High Grade Neuroendocrine Neoplasms

NCT04551430 2025-11-12

Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

105 enrolled

NCT05836571 2025-10-20

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

66 enrolled

Sarcoma, Histiocytoma, Malignant Fibrous

NCT03635892 2025-09-22

A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

60 enrolled

Carcinoma, Renal Cell

NCT05660954 2025-09-05

CABOTHYROID

41 enrolled

Head & Neck

Neoplasms, Thyroid Diseases

NCT04164979 2025-08-11

Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma

34 enrolled 11 charts

Gastrointestinal

Gastric Adenocarcinoma

NCT03367741 2025-07-28

Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

82 enrolled

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT03634540 2024-12-20

MK-6482-003

118 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT04289779 2024-12-04

ABATE

46 enrolled

Urinary Bladder Neoplasms

NCT04524208 2024-08-13

CABONEN

45 enrolled

EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT05289856 2024-03-07

Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)